Patents by Inventor Mitchell H. Keylor
Mitchell H. Keylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12570640Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4, X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.Type: GrantFiled: September 1, 2021Date of Patent: March 10, 2026Assignee: Merck Sharp & Dohme LLCInventors: John J. Acton, III, Ryan Chau, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, Solomon Kattar, Mitchell H. Keylor, Derun Li, Kaila A. Margrey, Gregori J. Morriello, Xin Yan
-
Patent number: 12540131Abstract: The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.Type: GrantFiled: October 20, 2020Date of Patent: February 3, 2026Assignee: Merck Sharp & Dohme LLCInventors: Mitchell H. Keylor, Michael J. Ardolino, Ryan W. Chau, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, Solomon D. Kattar, Kaila A. Margrey, Gregori J. Morriello, Santhosh F. Neelamkavil, Xin Yan, Elsie C. Yu, Cayetana Carmela Zarate Saez
-
Publication number: 20260022125Abstract: Provided are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are VEGFR inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.Type: ApplicationFiled: July 17, 2025Publication date: January 22, 2026Applicant: Merck Sharp & Dohme LLCInventors: Michael D. Altman, Yejin Chang, Duane DeMong, Robert P. Hayes, Mitchell H. Keylor, Chi Chip Le, Umar Faruk Mansoor, Shasha Feng, Kevin Anton Spiekermann
-
Patent number: 12516039Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.Type: GrantFiled: October 27, 2021Date of Patent: January 6, 2026Assignee: Merck Sharp & Dohme LLCInventors: Peter H. Fuller, Anmol Gulati, Solomon D. Kattar, Mitchell H. Keylor, Kaila A. Margrey, Xin Yan
-
Publication number: 20250313575Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I) and (Ia); and pharmaceutically acceptable salts thereof, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.Type: ApplicationFiled: May 15, 2023Publication date: October 9, 2025Applicant: Merck Sharp & Dohme LLCInventors: Elsie Yu, Peter Fuller, Hua Zhou, Kaitlyn M. Logan, Solomon D. Kattar, Anmol Gulati, Mitchell H. Keylor, Kelsey E. Poremba, Michael Joseph Ardolino, Xin Yan, Rachel L. Palte, Dong Xiao
-
Patent number: 12319671Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.Type: GrantFiled: June 1, 2020Date of Patent: June 3, 2025Assignee: Merck Sharp & Dohme LLCInventors: Hua Zhou, John J. Acton, III, Michael J. Ardolino, Yi-Heng Chen, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, William P. Kaplan, Solomon D. Kattar, Mitchell H. Keylor, Derun Li, Kaitlyn Marie Logan, Min Lu, Gregori J. Morriello, Santhosh F. Neelamkavil, Barbara Pio, Nunzio Sciammetta, Vladimir Simov, Jing Su, Luis Torres, Xin Yan
-
Publication number: 20240398784Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.Type: ApplicationFiled: September 26, 2022Publication date: December 5, 2024Applicant: Merck Sharp & Dohme LLCInventors: Peter H. Fuller, Anmol Gulati, Solomon D. Kattar, Mitchell H. Keylor, Kaila A. Margrey, Luis Torres, Xin Yan
-
Publication number: 20230406844Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.Type: ApplicationFiled: October 27, 2021Publication date: December 21, 2023Applicant: Merck Sharp & Dohme LLCInventors: Peter H. Fuller, Anmol Gulati, Solomon D. Kattar, Mitchell H. Keylor, Kaila A. Margrey, Xin Yan
-
Publication number: 20230303540Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4, X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.Type: ApplicationFiled: September 1, 2021Publication date: September 28, 2023Applicant: Merck Sharp & Dohme LLCInventors: John J. Acton, III, Ryan Chau, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, Solomon Kattar, Mitchell H. Keylor, Derun Li, Kaila A. Margrey, Gregori J. Morriello, Xin Yan
-
Publication number: 20230023066Abstract: The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.Type: ApplicationFiled: October 20, 2020Publication date: January 26, 2023Applicant: Merck Sharp & Dohme Corp.Inventors: Mitchell H. Keylor, Michael J. Ardolino, Ryan W. Chau, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, Solomon D. Kattar, Kaila A. Margrey, Gregori J. Morriello, Santhosh F. Neelamkavil, Xin Yan, Elsie C. Yu, Cayetana Carmela Zarate Saez
-
Publication number: 20220259188Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.Type: ApplicationFiled: June 1, 2020Publication date: August 18, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Hua Zhou, John J. Acton, III, Michael J. Ardolino, Yi-Heng Chen, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, William P. Kaplan, Solomon D. Kattar, Mitchell H. Keylor, Derun Li, Kaitlyn Marie Logan, Min Lu, Gregori J. Morriello, Santhosh F. Neelamkavil, Barbara Pio, Nunzio Sciammetta, Vladimir Simov, Jing Su, Luis Torres, Xin Yan